Our fabulous Senior Development Scientist Alex was interviewed recently about life at Pertinax. Find out what she had to say about our activities, challenges and aspirations here!
To read our case study, click here!
Pertinax Pharma are delighted to announce that they have secured funding from Innovation 4 Growth (I4G). I4G is a funding scheme managed by the University of the West of England and developed using the European Regional Development Fund. It supports SMEs in the West of England to develop innovative
Pertinax Pharma Ltd is delighted to announce the successful closing of its latest £860,000 funding round. The investment was provided by national investors Mercia Fund Managers and Perivoli Innovations, both following on, and new investor Syndicate Room. Peter Dines, Chief Operating Officer at
A paper describing the use of finely divided chlorhexidine hexametaphosphate particles in a glass ionomer cement has this week been accepted for publication in Dental Materials, the leading international journal for dental materials. The paper illustrates that by doping this important dental
We were delighted to receive the news this week that our patent, protecting Pertinax materials in any application, has been granted in China.
We are raising capital @SyndicateRoom. Our funding round is at 95% – for sophisticated investors only & @CapitalAtRisk - click for further information
We are delighted to announce that the Pertinax patents have been formally assigned to Pertinax Pharma. Previously, the patents were owned by the University of Bristol and licensed to the company on an exclusive, royalty-free basis. However, as of 2nd July the patents have been transferred to the